Abstract: The subject invention provides sensor systems that can detect biomarkers related to wound healing (e.g., uric acid, adenosine, arginine and/or xanthine). In one embodiment, the subject invention pertains to materials and methods for monitoring biomarkers non-invasively in a wound and a biofluid (e.g., sweat) in the proximity of the wound, optionally, including other physiological fluids. Skin based, non-invasive enzymatic electrochemical biosensor on a wearable platform (e.g., sweat patch) that can evaluate the healing of wounds through assessment of its biomarker levels are provided. This non-invasive detection from physiologically biofluids can reduce or eliminate occlusion effects.

Abstract: An ingestible capsule device collects fluid aspirates from locations within the body, locations such as the small intestine, and retains the fluid aspirates free from contamination as the capsule device is expelled from the body. The device allows for microbial and metabolomics analysis for a variety of gastrointestinal, allergic, endocrinologic, and oncologic diseases. In some examples, the capsule device is a multi-stroke device that includes a capsule shell and two reservoirs located within the shell. Check valves work in conjunction with a vacuum pressure pumping mechanism to control fluid movement from one reservoir to another, where one of the reservoirs may be expandable and permeable to some fluids. In other examples, the capsule device employs a peristaltic pump fluid control with the capsule device, and a single semi-permeable bladder stores collected fluid aspirate.

Abstract: In certain embodiments, enhancement of a vision of a user may be facilitated. In some embodiments, a visual test presentation including a set of stimuli may be provided to a user. Feedback related to the set of stimuli may be obtained during the visual test presentation. The feedback may be provided to a prediction model, and the prediction model may be configured based on the feedback. Subsequent to the configuring of the prediction model, live video stream data, eye characteristic information, or other information may be provided to the prediction model to obtain a set of modification parameters. A modified version of the live video stream data may be generated and displayed to the user based on the live video stream and the set of modification parameters.

Abstract: In some embodiments, initial feedback indicating threshold characteristics (under which a user sees initial stimuli presented on a user interface) may be provided to a prediction model, and a set of predicted characteristics (for a set of locations of the user interface) and a set of confidence scores associated with the set of locations may be obtained via the prediction model. Based on the set of confidence scores, one or more locations may be selected to be tested during a visual test presentation. As an example, the locations may be selected over one or more other locations of the set of locations based on the set of confidence scores. Based on predicted characteristics associated with the selected locations, stimuli may be presented at the selected locations during the visual test presentation. Visual defect information for the user may be generated based on feedback from the visual test presentation.

Abstract: Topical formulations of CoQ10 reduce the rate of tumor growth in an animcal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

Abstract: A method is disclosed for improving accuracy of visual field testing in head-mounted displays. The method includes retrieving a visual field testing pattern for a head-mounted display, the visual field testing pattern including icons displayed at respective locations in a visual field of the head-mounted display. The visual field testing pattern is generated on the head-mounted display. Data is retrieved from a tilt sensor, located at the head-mounted display, for detecting degrees of head tilt of a user wearing the head-mounted display and the degree of head tilt is determined. A comparison is made between the degree of head tilt of the user to a first threshold degree. In response to the degree of head tilt of the user meeting or exceeding the first threshold degree, a recommendation to the user is generated for display on the head-mounted display.

Abstract: In certain embodiments, enhancement of a vision of a user may be facilitated. In some embodiments, a visual test presentation including a set of stimuli may be provided to a user. Feedback related to the set of stimuli may be obtained during the visual test presentation. The feedback may be provided to a prediction model, and the prediction model may be configured based on the feedback. Subsequent to the configuring of the prediction model, live video stream data, eye characteristic information, or other information may be provided to the prediction model to obtain a set of modification parameters. A modified version of the live video stream data may be generated and displayed to the user based on the live video stream and the set of modification parameters.

Abstract: In certain embodiments, vision defect information may be generated via a dynamic eye-characteristic-based fixation point. In some embodiments, a first stimulus may be displayed at a first location on a user interface based on a fixation point for a visual test presentation. The fixation point for the visual test presentation may be adjusted during the visual test presentation based on eye characteristic information related to a user. As an example, the eye characteristic information may indicate a characteristic of an eye of the user that occurred during the visual test presentation. A second stimulus may be displayed during the visual test presentation at a second interface location on the user interface based on the adjusted fixation point for the visual test presentation. Vision defect information associated with the user may be generated based on feedback information indicating feedback related to the first stimulus and feedback related to the second stimulus.

Abstract: The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating multiple sclerosis.

Abstract: Systems and methods for quantitatively imaging retinal blood vessel oxygen saturation using retinal auto-fluorescence (AF) are provided. One or more excitation sources can be used to provide light to the retina, and retinal AF can be detected by one or more detectors. The quantitative level of oxygen saturation in the blood can be determined based on the intensity of AF.

Abstract: In certain embodiments, enhancement of a field of view of a user may be facilitated via one or more dynamic display portions. In some embodiments, one or more changes related to one or more eyes of a user may be monitored. Based on the monitoring, one or more positions of one or more transparent display portions of wearable device may be adjusted, where the transparent display portions enable the user to see through the wearable device. A live video stream representing an environment of the user may be obtained via the wearable device. A modified video stream derived from the live video stream may be displayed on one or more other display portions of the wearable device.

Abstract: Compositions specific for TNF-receptor superfamily member 25 (TNFRSF25, DR3) modulate the immune re-sponse by regulating T regulatory cells.

Abstract: In some embodiments, a set of eye images related to a subject may be provided to a prediction model. A first prediction may be obtained via the prediction model, where the first prediction is derived from a first eye image and indicates whether an eye condition is present in the subject. A second prediction may be obtained via the prediction model, where the second prediction is derived from a second eye image and indicates that the eye condition is present in the subject. An aspect associated with the first prediction may be adjusted via the prediction model based on the second prediction's indication that the eye condition is present in the subject. One or more predictions related to at least one eye condition for the subject may be obtained from the prediction model, where the prediction model generates the predictions based on the adjustment of the first prediction.

Abstract: The present disclosure provides, in general, a method for selecting a therapy for treating cancer in a human subject and subsequently treating cancer in a subject, which includes isolating a cancer cell from a human subject having cancer, determining the functional activity of the innate immune regulator STimulator of INterferon Genes (STING) or the cellular nucleotidyltransferase, cyclic Guanosine Monophosphate (cGMP)—Adenosine Monophosphate (AMP) Synthase (cyclicGMP-AMP Synthase or cGAS) in the cell, and selecting a therapy for the cancer based on the functional activity of the STING or cGAS in the cell. Also provided, if the functional activity of STING and/or cGAS is determined to be defective in the cell, the therapy selected is one that is effective at killing STING-deficient and/or cGAS-deficient cancer cells, for example a therapy including administering to the subject an oncolytic virus.

Abstract: The present disclosure relates, in general, to recombinant viral vectors that stimulate STING (STimulator of INterferon Genes) activity and increase activity of immune cells.

Abstract: The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAP?. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAP? to which PP2A binds.

Abstract: In some embodiments, a set of eye images related to a subject may be provided to a prediction model. A first prediction may be obtained via the prediction model, where the first prediction is derived from a first eye image and indicates whether an eye condition is present in the subject. A second prediction may be obtained via the prediction model, where the second prediction is derived from a second eye image and indicates that the eye condition is present in the subject. An aspect associated with the first prediction may be adjusted via the prediction model based on the second prediction's indication that the eye condition is present in the subject. One or more predictions related to at least one eye condition for the subject may be obtained from the prediction model, where the prediction model generates the predictions based on the adjustment of the first prediction.

Abstract: Compositions and methods of activating dendritic cells with LMP1 and LMP1-activated dendritic cell based compositions and methods are effective for dendritic cell therapy and provide an adjuvant function for vaccine administration. LMP1 or LMP1-CD40 chimeric protein may be used to activate and mature dendritic cells. LMP1 and LMP1-activated dendritic cells act as an adjuvant to enhance the cellular immune response. Also disclosed herein are kits for activating dendritic cells and for preparing a vaccine formulation. Administration of the dendritic cells transfected with LMP1 can induce an immune response against cancer or infection. The mature dendritic cells may comprise an antigen and at least one cytokine in addition to LMP1. Use of LMP1 or LMP1-CD40 provides a way to activate and mature dendritic cells that retain functional and migratory abilities without the side effects that result from maturing the dendritic cells using PGE2.

Abstract: Kits and methods for detecting pathogens without the need for laboratory equipment are disclosed. The kits and methods described herein allow for near-room temperature amplification of pathogen polynucleotides in a biological sample in a one-compartment reaction vessel. The kits and methods may be used to detect any target nucleic acid, such as DNA or RNA from a bacterial, fungal, or viral pathogen.

Abstract: Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).